Welcome to the Newsroom
12 May 2016
Prima BioMed enters into Sale and Licensing Agreement with SYDYS to advance CVac™ Program
- Sydys Licenses Clinical‐Stage Immuno‐oncology Assets in ‘spin out’ transaction
- Potential for over A$400M in milestones and royalties
- Prima to receive 9.9% equity in Sydys
SYDNEY, AUSTRALIA and SEATTLE, WASHINGTON ‐ Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) and U.S.‐based Sydys Corporation, Inc. (OTC: SYYC) (“Sydys”), today announced an agreement through which Sydys will license Prima’s CVac™ immuno‐oncology program and oversee its future development.
Article as pdf